CGTX
Cognition Therapeutics Inc

3,866
Mkt Cap
$122.7M
Volume
1.17M
52W High
$3.83
52W Low
$0.2223
PE Ratio
-2.93
CGTX Fundamentals
Price
$1.33
Prev Close
$1.39
Open
$1.42
50D MA
$1.63
Beta
1.48
Avg. Volume
1.77M
EPS (Annual)
-$0.855
P/B
3.36
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Cognition Therapeutics (NASDAQ:CGTX) Announces Quarterly Earnings Results
Cognition Therapeutics (NASDAQ:CGTX - Get Free Report) announced its earnings results on Thursday. The company reported ($0.06) earnings per share for the quarter, topping analysts' consensus...
MarketBeat·11d ago
News Placeholder
More News
News Placeholder
Cognition Therapeutics (NASDAQ:CGTX) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen raised shares of Cognition Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·11d ago
News Placeholder
Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year?
Here is how ANI Pharmaceuticals (ANIP) and Cognition Therapeutics, Inc. (CGTX) have performed compared to their sector so far this year.
Zacks·24d ago
News Placeholder
Cognition Therapeutics (CGTX) Moves to Buy: Rationale Behind the Upgrade
Cognition Therapeutics (CGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·1mo ago
News Placeholder
Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference
PURCHASE, N.Y., April 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the Company or Cognition ) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative...
Globe Newswire·2y ago
News Placeholder
Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer's Disease on April 12, 2024
NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the Company or Cognition ) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative...
Globe Newswire·2y ago
News Placeholder
B. Riley Reiterates "Buy" Rating for Cognition Therapeutics (NASDAQ:CGTX)
Cognition Therapeutics (NASDAQ:CGTX - Get Free Report)s stock had its "buy" rating restated by investment analysts at B. Riley in a research note issued on Thursday, Benzinga reports. They...
Zolmax·2y ago
News Placeholder
Q4 2023 Cognition Therapeutics Inc Earnings Call Transcript
Related Stocks: NAS:CGTX...
GuruFocus·2y ago
News Placeholder
Cognition Therapeutics reports FY results
Cognition Therapeutics reports FY results...
SeekingAlpha.com: All News·2y ago
News Placeholder
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
- Topline Results from SHINE Study in Mild-to-Moderate Alzheimer's Expected mid-2024 -- On Track to Report Topline Results from SHIMMER Study in Mild-to-Moderate DLB in 2H 2024 - - 1Q 2024 Capital...
Globe Newswire·2y ago

Latest CGTX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.